SUMO1, human recombinant protein
Small ubiquitin-related modifier 1, SUMO-1, Sentrin, Ubiquitin-like protein SMT3C, SMT3 homolog 3, U
|Calculated MW||11.1 kDa|
|Other Names||Small ubiquitin-related modifier 1, SUMO-1, Sentrin, Ubiquitin-like protein SMT3C, SMT3 homolog 3, Ubiquitin-homology domain protein PIC1, Ubiquitin-like protein UBL1, GAP-modifying protein 1, GMP1, SUMO1, SMT3C, SMT3H3, UBL1, PIC1, SMT3, DAP-1, OFC10, SENP2.|
|Storage||-80°C; In 50 mM HEPES, pH 8.0, plus 150 mM NaCl, 1 mM DTT.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
SUMO modification has been implicated in functions such as nuclear transport, chromosome segregation and transcriptional regulation. SUMO1 functions in a manner similar to ubiquitin in that it is bound to target proteins as part of a post-translational modification system. Still, unlike ubiquitin which targets proteins for degradation, SUMO1 is involved in a variety of Cellular processes, for example nuclear transport, transcriptional regulation, apoptosis, and protein stability. SUMO1 is not active until the last four amino acids of the carboxy-terminus are cleaved off. The active recombinant SUMO-1 protein is derived from the precursor pro-SUMO-1 (Accession # NM_003352). Human SUMO-1 shares 46% and 47% identity with SUMO-2 and SUMO-3 respectively. SUMOylation can occur without the requirement of a specific E3 ligase activity, where SUMO is transferred directly from UbcH9 to specific substrates. SUMOylated substrates are primarily localized to the nucleus (RanGAP-1, RANBP2, PML, p53, Sp100, HIPK2) but there are also cytosolic substrates (IκBα, GLUT1, GLUT4).
Lapenta V.,et al.Genomics 40:362-367(1997).
Boddy M.N.,et al.Oncogene 13:971-982(1996).
Shen Z.,et al.Genomics 36:271-279(1996).
Mahajan R.,et al.Cell 88:97-107(1997).
Matunis M.J.,et al.J. Cell Biol. 135:1457-1470(1996).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.